SORAFENIB IN PATIENTS WITH RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER

被引：0

作者：

Horiike, Atsushi ^{[1
]}

Takeuchi, Kengo ^{[2
]}

Uenami, Takeshi ^{[1
]}

Kawano, Yuko ^{[1
]}

Tanimoto, Azusa ^{[1
]}

Kaburaki, Kyohei ^{[1
]}

Kobayashi, Hiroshi ^{[1
]}

Gyotoku, Hiroshi ^{[1
]}

Nishizawa, Hironari ^{[1
]}

Tambo, Yuichi ^{[1
]}

Nakatomi, Katsumi ^{[1
]}

Yanagitani, Noriko ^{[1
]}

Ohyanagi, Fumiyoshi ^{[1
]}

Hagiwara, Sachiko ^{[1
]}

Motoi, Noriko ^{[3
]}

Ishikawa, Yuichi ^{[3
]}

Horai, Takeshi ^{[1
]}

Nishio, Makoto ^{[1
]}

机构：

[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Thorac Med Oncol, Tokyo, Japan

[2] Japanese Fdn Canc Res, Pathol Project Mol Targets, Tokyo, Japan

[3] Japanese Fdn Canc Res, Inst Canc, Div Pathol, Tokyo, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷

关键词：

RET; Sorafenib;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2.11-020

引用

页码：S898 / S898

页数：1

共 50 条

[1] Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer
Horiike, Atsushi
Takeuchi, Kengo
Uenami, Takeshi
Kawano, Yuko
Tanimoto, Azusa
Kaburaki, Kyohei
Tambo, Yuichi
Kudo, Keita
Yanagitani, Noriko
Ohyanagi, Fumiyoshi
Motoi, Noriko
Ishikawa, Yuichi
Horai, Takeshi
Nishio, Makoto
[J]. LUNG CANCER, 2016, 93 : 43 - 46
[2] Targeted therapy of RET fusion-positive non-small cell lung cancer
Shen, Zixiong
Qiu, Binxu
Li, Lin
Yang, Bo
Li, Guanghu
[J]. FRONTIERS IN ONCOLOGY, 2022, 12
[3] RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape
Novello, Silvia
Califano, Raffaele
Reinmuth, Niels
Tamma, Antonella
Puri, Tarun
[J]. ONCOLOGIST, 2023, 28 (05): : 402 - 413
[4] Pralsetinib: Treatment of metastatic RET fusion-positive non-small cell lung cancer
Nguyen, Ly
Monestime, Shanada
[J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (07) : 527 - 533
[5] Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer
Fangdi Sun
Caroline E. McCoach
[J]. Current Treatment Options in Oncology, 2021, 22
[6] Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer
Zhou, Qing
Zhao, Jun
Chang, Jianhua
Wang, Huijie
Fan, Yun
Wang, Ke
Wu, Gang
Nian, Weiqi
Sun, Yuping
Sun, Meili
Wang, Xiangcai
Shi, Huaqiu
Zheng, Xiangqian
Yao, Sheng
Qin, Mengmeng
Shen, Zhenwei
Yang, Jason
Wu, Yi-Long
[J]. CANCER, 2023, 129 (20) : 3239 - 3251
[7] Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer
Sun, Fangdi
McCoach, Caroline E.
[J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2021, 22 (08)
[8] Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer
Gao, Ming
Zhang, Xia
Yan, Huan
Sun, Decong
Yang, Xuejiao
Yuan, Fang
Ju, Yanfang
Wang, Lijie
Wang, Jinliang
Zhao, Wei
Zhang, Dong
Li, Lin
Xu, Xiaoyun
Ma, Junxun
Hu, Yi
Zhang, Xiaotao
[J]. SUPPORTIVE CARE IN CANCER, 2023, 31 (12)
[9] Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer
Ming Gao
Xia Zhang
Huan Yan
Decong Sun
Xuejiao Yang
Fang Yuan
Yanfang Ju
Lijie Wang
Jinliang Wang
Wei Zhao
Dong Zhang
Lin Li
Xiaoyun Xu
Junxun Ma
Yi Hu
Xiaotao Zhang
[J]. Supportive Care in Cancer, 2023, 31
[10] Pralsetinib in patients with RET fusion-positive non-small cell lung cancer: A plain language summary of the ARROW study
Griesinger, Frank
Curigliano, Giuseppe
Subbiah, Vivek
Baik, Christina S.
Tan, Daniel S. W.
Lee, Dae H.
Misch, Daniel
Garralda, Elena
Kim, Dong-Wan
van der Wekken, Anthonie J.
Gainor, Justin F.
Paz-Ares, Luis
Liu, Stephen, V
Kalemkerian, Gregory P.
Bowles, Daniel W.
Mansfield, Aaron S.
Lin, Jessica J.
Smoljanovic, Vlatka
Rahman, Ahmadur
Zalutskaya, Alena
Louie-Gao, Melinda
Boral, Andy L.
Mazieres, Julien
[J]. FUTURE ONCOLOGY, 2024, 20 (06) : 297 - 306

← 1 2 3 4 5 →